Recurrent Clostridium Difficile Infection: An Immunodeficiency State?

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 6, 2007, Pages 672-673

  Pardi, Darrell S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PROBIOTIC AGENT; TOXIN ANTIBODY; VACCINE;

BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; DRUG RESEARCH; EDITORIAL; EXPERIMENTAL MODEL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTIOUS DIARRHEA; NONHUMAN; PASSIVE IMMUNIZATION; T LYMPHOCYTE; TREATMENT PLANNING; VACCINATION;

ANTIBODY FORMATION; BACTERIAL PROTEINS; BACTERIAL TOXINS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; HUMANS; RECURRENCE;

EID: 34249727246     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.03.025     Document Type: Editorial

References (31)

1. Bartlett J.G., and Perl T.M. The new Clostridium difficile: what does it mean?. N Engl J Med 353 (2005) 2503-2505
2. Maroo S., and Lamont J. Recurrent Clostridium difficile. Gastroenterology 130 (2006) 1311-1316
3. Kyne L., and Kelly C.P. Prospects for a vaccine for Clostridium difficile. Biodrugs 10 (1998) 173-181
4. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000) 390-397
5. Mulligan M.E., Miller S.D., McFarland L.V., et al. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 16 Suppl 4 (1993) S239-S244
6. Johnson S., Gerding D.N., and Janoff E.N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 166 (1992) 1287-1294
7. Warny M., Vaerman J.P., Avesani V., et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 62 (1994) 384-389
8. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 357 (2001) 189-193
9. Leung D.Y., Kelly C.P., Boguniewicz M., et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118 (1991) 633-637
10. Aronsson B., Granstrom M., Mollby R., et al. Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea. J Immunol Methods 60 (1983) 341-350
11. Aronsson B., Granstrom M., Mollby R., et al. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13 (1985) 97-101
12. Nakamura S., Mikawa M., Nakashio S., et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 25 (1981) 345-351
13. Hassett J., Meyers S., McFarland L., et al. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 20 Suppl 2 (1995) S266-S268
14. McPherson S., Rees C.J., Ellis R., et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 49 (2006) 640-645
15. Murphy C., Vernon M., and Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 35 (2006) 85-86
16. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53 (2004) 882-884
17. Salcedo J., Keates S., Pothoulakis C., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41 (1997) 366-370
18. Babcock G., Broering T., Hernandez H., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74 (2006) 6339-6347
19. Corthier G., Muller M.C., Wilkins T.D., et al. Protection against experimental pseudomembranous colitis in gnobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immunol 59 (1991) 1192-1195
20. Kim P.H., Iaconis J.P., and Rolfe R.D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immunol 55 (1987) 2984-2992
21. van Dissel J.T., de Groot N., Hensgens C.M., et al. Bovine antibody enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54 (2005) 197-205
22. Sougioultzis S., Kyne L., Drudy D., et al. Clostridium difficile toxoid vaccine in recurrent C difficile-associated diarrhea. Gastroenterology 128 (2005) 764-770
23. Katchar K., Taylor C.P., Tummala S., et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile associated disease. Clin Gastroenterol Hepatol 5 (2007) 707-713
24. Yoshida M., Masuda A., Kuo T.T., et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol 28 (2006) 397-403
25. West Jr. A.P., and Bjorkman P.J. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39 (2000) 9698-9708
26. Oxelis V.A., Aurivillius M., Carlsson A.M., and Musil K. Serum Gm allotype development during childhood. Scand J Immunol 50 (1999) 440-446
27. Oxelis V.A. Serum IgG and IgG subclass contents in different Gm phenotypes. Scand J Immunol 37 (1993) 149-153
28. Ochs H.D., and Wedgwood R.J. IgG subclass deficiencies. Annu Rev Med 38 (1987) 325-340
29. Jefferis R., and Kumararatne D.S. Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol 81 (1990) 357-367
30. Pan Q., and Hammarstrom L. Molecular basis of IgG subclass deficiency. Immunol Rev 178 (2000) 99-110
31. Stubbe H., Berdoz J., Kraehenbuhl J.-P., et al. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol 164 (2000) 1952-1960